Showing results (61-70 of 65) with videos related to
Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 65 results.
Targeted Oncology|November 3, 2025
Amivantamab-Chemotherapy in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertions: Impact of Treatment Crossover and Other Endpoints from the Phase III PAPILLON StudyRachel E Sanborn, Caicun Zhou, Ke-Jing Tang, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2021
Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I StudyKeunchil Park, Eric B Haura, Natasha B Leighl, et al.European Journal of Cancer (Oxford, England : 1990)|July 29, 2025
Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated non-small cell lung cancer: Patient satisfaction and resource utilization results from the PALOMA-3 studyMariam Alexander, Ying Cheng, Se-Hoon Lee, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 4, 2025
Amivantamab Plus Lazertinib in Patients With EGFR-Mutant NSCLC After Progression on Osimertinib and Platinum-Based Chemotherapy: Results From CHRYSALIS-2 Cohort ABenjamin Besse, Koichi Goto, Yongsheng Wang, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 10, 2024
Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 StudyNatasha B Leighl, Hiroaki Akamatsu, Sun Min Lim, et al.Pageof 7